BioCellgraft, Inc. is a biotechnology and regenerative medicine company identifying, developing, commercializing, and distributing innovative regenerative solutions—led by our flagship product platform, OraFyl®.
This corporate site may include forward-looking statements about future objectives and potential development areas.
We start with biology—then translate it into real-world clinical workflows.
Handling, consistency, storage, shelf-life, and repeatability matter.
Quality mindset, documentation discipline, and clear communication are non-negotiable.
The future of regenerative oral health will be defined by solutions that meet real-world clinical needs.
Our goal is to build what clinicians wish existed—then validate it with discipline.
ECM-inspired biomaterial platforms
Flowable and deliverable formats designed for procedural workflows
Barrier and membrane concepts aligned with surgical handling needs
Next-generation oral regeneration candidates under evaluation for future development
In our view, the ideal regenerative oral health product would be exceptionally capable, broadly useful, and operationally simple—high performance without unnecessary complexity; stable yet adaptable; long shelf-life without special handling burdens; and designed to fit seamlessly into modern clinical workflows.
This is our north star: build what clinicians wish existed—then prove it the right way.